Deciphera upgraded to Buy from Hold at JonesResearch

JonesResearch upgraded Deciphera to Buy from Hold with a $168 price target. The company’s earnings conitnue to beat expectations, the analyst tells investors in a research note. With positive outcome in TGCT and better than expected revenue, the firm updated its model, increasing the probability of success for vimseltinib in TGCT to 80% from 60%, duration of vimseltinib treatment to 15 months from 10 months and adjusted expected future revenue.